|
|
|
|
|
|
|
Mon T W Th F |
|
18 May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Merck and China-based Kelun-Biotech scored a Phase 3 victory with their experimental antibody-drug conjugate in advanced endometrial cancer, Max Gelman reports. Meanwhile, Lei Lei Wu unpacks a new up-to-$2.2 billion deal between Regeneron and Parabilis Medicines, for the smaller company’s swings at formerly “undruggable” cancer targets. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Mathai Mammen, Parabilis Medicines CEO (via FogPharma) |
|
|
|
by Lei Lei Wu
|
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued... | |
|
|
|
|
|
|
by Max Gelman
|
An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led... | |
|
|
|
|
|
|
|
|
by Ayisha Sharma
|
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a... | |
|
|
|
|
|
